Nurix Therapeutics, Inc. (NRIX) Misses Q3 EPS by 20c

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($1.03), $0.20 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $7.89 million versus the consensus estimate of $16.05 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
• Matrix Service wins FEED contract for Texas refinery tank farm
• PVH Corp. (PVH) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY27 EPS Guidance